BRPI0821069A2 - Derivados de oxadiazol ativos em 1-fosfa de esfingosina (s1p) - Google Patents
Derivados de oxadiazol ativos em 1-fosfa de esfingosina (s1p)Info
- Publication number
- BRPI0821069A2 BRPI0821069A2 BRPI0821069-1A BRPI0821069A BRPI0821069A2 BR PI0821069 A2 BRPI0821069 A2 BR PI0821069A2 BR PI0821069 A BRPI0821069 A BR PI0821069A BR PI0821069 A2 BRPI0821069 A2 BR PI0821069A2
- Authority
- BR
- Brazil
- Prior art keywords
- sphingosine
- phosphate
- oxadiazole derivatives
- derivatives active
- active
- Prior art date
Links
- 150000004866 oxadiazoles Chemical class 0.000 title 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0725101.0A GB0725101D0 (en) | 2007-12-21 | 2007-12-21 | Compounds |
| PCT/EP2008/067963 WO2009080724A1 (en) | 2007-12-21 | 2008-12-19 | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0821069A2 true BRPI0821069A2 (pt) | 2015-06-16 |
Family
ID=39048651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0821069-1A BRPI0821069A2 (pt) | 2007-12-21 | 2008-12-19 | Derivados de oxadiazol ativos em 1-fosfa de esfingosina (s1p) |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8278324B2 (pt) |
| EP (2) | EP2225233B1 (pt) |
| JP (1) | JP2011506568A (pt) |
| KR (1) | KR20100108568A (pt) |
| CN (1) | CN101945864A (pt) |
| AU (1) | AU2008339987B2 (pt) |
| BR (1) | BRPI0821069A2 (pt) |
| CA (1) | CA2710067A1 (pt) |
| CO (1) | CO6290688A2 (pt) |
| CR (1) | CR11578A (pt) |
| DK (1) | DK2225233T3 (pt) |
| DO (1) | DOP2010000187A (pt) |
| EA (1) | EA018637B1 (pt) |
| ES (1) | ES2431795T3 (pt) |
| GB (1) | GB0725101D0 (pt) |
| HR (1) | HRP20131053T1 (pt) |
| IL (1) | IL206278A0 (pt) |
| MA (1) | MA31922B1 (pt) |
| NZ (1) | NZ585994A (pt) |
| PL (1) | PL2225233T3 (pt) |
| PT (1) | PT2225233E (pt) |
| UA (1) | UA102539C2 (pt) |
| WO (1) | WO2009080724A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| GB0725101D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| EP2481740B1 (en) * | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| SI2958913T1 (sl) | 2013-02-20 | 2018-12-31 | Lg Chem, Ltd. | Sfingozin-1-fosfat receptor agonisti, postopki za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo kot aktivno sredstvo |
| CA3066423A1 (en) * | 2017-06-14 | 2018-12-20 | Trevena, Inc. | Compounds for modulating s1p1 activity and methods of using the same |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Edg受容体アゴニストとしての1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)アゼチジン−3−カルボキシラートおよび1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)ピロリジン−3−カルボキシラート |
| WO2004113330A1 (en) | 2003-05-19 | 2004-12-29 | Irm Llc | Immunosuppressant compounds and compositions |
| MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| AU2004251146A1 (en) * | 2003-05-19 | 2005-01-06 | Irm, Llc | Immunosuppressant compounds and compositions |
| CN1787817B (zh) * | 2003-05-19 | 2011-09-07 | Irm责任有限公司 | 免疫抑制剂化合物及组合物 |
| AU2004299456B2 (en) * | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| JP5315611B2 (ja) * | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
| JP2008517915A (ja) * | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | S1p受容体アゴニストとしての2−(アリール)アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
| JP4318087B2 (ja) | 2004-12-13 | 2009-08-19 | 小野薬品工業株式会社 | アミノカルボン酸誘導体およびその医薬用途 |
| BRPI0609668A2 (pt) * | 2005-03-23 | 2011-10-18 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| CN101203512A (zh) * | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
| JP2008545767A (ja) * | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびsip受容体リガンドとしてのそれらの使用 |
| JP2009506046A (ja) * | 2005-08-23 | 2009-02-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制剤化合物および組成物 |
| MX2008012738A (es) * | 2006-04-03 | 2009-02-06 | Astellas Pharma Inc | Heterocompuesto. |
| WO2008064337A2 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| GB0725101D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| GB0725104D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
-
2007
- 2007-12-21 GB GBGB0725101.0A patent/GB0725101D0/en not_active Ceased
-
2008
- 2008-12-19 EA EA201070781A patent/EA018637B1/ru not_active IP Right Cessation
- 2008-12-19 US US12/747,191 patent/US8278324B2/en not_active Expired - Fee Related
- 2008-12-19 AU AU2008339987A patent/AU2008339987B2/en not_active Ceased
- 2008-12-19 CA CA2710067A patent/CA2710067A1/en not_active Abandoned
- 2008-12-19 WO PCT/EP2008/067963 patent/WO2009080724A1/en not_active Ceased
- 2008-12-19 EP EP08863529.7A patent/EP2225233B1/en active Active
- 2008-12-19 KR KR1020107016169A patent/KR20100108568A/ko not_active Ceased
- 2008-12-19 DK DK08863529.7T patent/DK2225233T3/da active
- 2008-12-19 NZ NZ585994A patent/NZ585994A/en not_active IP Right Cessation
- 2008-12-19 ES ES08863529T patent/ES2431795T3/es active Active
- 2008-12-19 PT PT88635297T patent/PT2225233E/pt unknown
- 2008-12-19 EP EP13182453.4A patent/EP2746254A3/en not_active Withdrawn
- 2008-12-19 JP JP2010538740A patent/JP2011506568A/ja not_active Ceased
- 2008-12-19 BR BRPI0821069-1A patent/BRPI0821069A2/pt not_active IP Right Cessation
- 2008-12-19 HR HRP20131053AT patent/HRP20131053T1/hr unknown
- 2008-12-19 CN CN2008801273526A patent/CN101945864A/zh active Pending
- 2008-12-19 UA UAA201009200A patent/UA102539C2/ru unknown
- 2008-12-19 PL PL08863529T patent/PL2225233T3/pl unknown
-
2010
- 2010-02-24 US US12/711,318 patent/US20100152235A1/en not_active Abandoned
- 2010-06-10 IL IL206278A patent/IL206278A0/en unknown
- 2010-06-16 MA MA32924A patent/MA31922B1/fr unknown
- 2010-06-18 DO DO2010000187A patent/DOP2010000187A/es unknown
- 2010-06-21 CO CO10074471A patent/CO6290688A2/es active IP Right Grant
- 2010-07-21 CR CR11578A patent/CR11578A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20100152235A1 (en) | 2010-06-17 |
| AU2008339987A1 (en) | 2009-07-02 |
| JP2011506568A (ja) | 2011-03-03 |
| IL206278A0 (en) | 2010-12-30 |
| US8278324B2 (en) | 2012-10-02 |
| EP2746254A3 (en) | 2014-10-15 |
| KR20100108568A (ko) | 2010-10-07 |
| EP2225233A1 (en) | 2010-09-08 |
| GB0725101D0 (en) | 2008-01-30 |
| ES2431795T3 (es) | 2013-11-28 |
| CA2710067A1 (en) | 2009-07-02 |
| PL2225233T3 (pl) | 2014-01-31 |
| US20100273827A1 (en) | 2010-10-28 |
| NZ585994A (en) | 2012-02-24 |
| CR11578A (es) | 2010-09-23 |
| AU2008339987B2 (en) | 2013-03-21 |
| DK2225233T3 (da) | 2013-10-14 |
| PT2225233E (pt) | 2013-11-22 |
| MA31922B1 (fr) | 2010-12-01 |
| EP2225233B1 (en) | 2013-09-04 |
| EA018637B1 (ru) | 2013-09-30 |
| DOP2010000187A (es) | 2010-08-15 |
| CN101945864A (zh) | 2011-01-12 |
| HRP20131053T1 (hr) | 2013-12-06 |
| WO2009080724A1 (en) | 2009-07-02 |
| EP2746254A2 (en) | 2014-06-25 |
| CO6290688A2 (es) | 2011-06-20 |
| EA201070781A1 (ru) | 2010-12-30 |
| UA102539C2 (ru) | 2013-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0820131A2 (pt) | Derivados de oxadiazol ativos em esfingosina-1-fosfato (s1p) | |
| CY2020036I2 (el) | Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p | |
| IL200870A0 (en) | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists | |
| LTC2379069I2 (lt) | S1p receptoriaus agonisto dozavimas | |
| BRPI0818457A2 (pt) | Derivados de oxadiazol | |
| BRPI1009274A2 (pt) | arquitetura de memória virtual sem uniformidade para máquinas virtuais | |
| BRPI0919548A2 (pt) | pacote para inserto | |
| EP2364089A4 (en) | Heterocyclic sphingosine-1-phosphate analogues | |
| BRPI1013422A2 (pt) | derivados de oxadiazol | |
| IL206278A0 (en) | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) | |
| BRPI0918935A2 (pt) | compostos amida úteis em terapia | |
| DE502008002369D1 (de) | Kühlmittelzuführung | |
| BR112013013648A2 (pt) | derivados de fenil oxadiazol como moduladores de receptor de esfingosina-1-fosfato(s1p) | |
| IL224071B (en) | 5-(biphenyl-r-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors | |
| EP1981154A4 (en) | DYNAMOELECTRIC MACHINE | |
| DE602007003680D1 (de) | Anästhesiegerätanordnung | |
| BRPI0815299A2 (pt) | estabilizantes fosfito para composto ionoméricos de poliester | |
| EP2045896A4 (en) | DYNAMOELECTRIC MACHINE | |
| EP1997881A4 (en) | TUBERCULOSIS VACCINE | |
| ES1069167Y (es) | Maquina para tatuar | |
| FI20075394L (fi) | Polttoaineen syöttöjärjestelmän polttoainevarasto | |
| GB0722340D0 (en) | Sphingosine-1-phosphate (S1P) receptor compounds | |
| ZA200906256B (en) | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | |
| ES1068918Y (es) | Ficha armable perfeccionada para juegos | |
| HK1142071A (en) | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |